The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
XELOX with bevacizumab in elderly patients age 75 or older with metastatic colorectal cancer: Results of a planned interim analysis for multicenter phase II ASCA study.
Keiichiro Ishibashi
No relevant relationships to disclose
Yoshinori Munemoto
No relevant relationships to disclose
Masaki Matsuoka
No relevant relationships to disclose
Taishi Hata
No relevant relationships to disclose
Michiya Kobayashi
No relevant relationships to disclose
Junichi Hasegawa
No relevant relationships to disclose
Mutsumi Fukunaga
No relevant relationships to disclose
Akinori Takagane
No relevant relationships to disclose
Toshio Otsuji
No relevant relationships to disclose
Yasuhiro Miyake
No relevant relationships to disclose
Michitaka Nagase
No relevant relationships to disclose
Koji Oba
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose
Hideyuki Mishima
No relevant relationships to disclose